Palisade Bio (PALI) Equity Average (2011 - 2026)

Palisade Bio (PALI) has 16 years of Equity Average data on file, last reported at $128.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $128.4 million, up 1902.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $128.4 million (up 1902.2% YoY), and the FY2025 annual result was $68.4 million, up 627.85% from the prior year.
• Equity Average improved to $128.4 million in Q1 2026 per PALI's latest filing, from $66.3 million in the prior quarter.
• Over five years, Equity Average peaked at $128.4 million in Q1 2026 and troughed at $2.9 million in Q3 2025.
• A 5-year average of $19.5 million and a median of $10.0 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2025 and 2026: Equity Average tumbled 64.78% in 2025, then surged 1902.2% in 2026.
• A 5-year view of Equity Average shows it stood at $12.5 million in 2022, then rose by 1.95% to $12.7 million in 2023, then sank by 44.48% to $7.0 million in 2024, then jumped by 840.37% to $66.3 million in 2025, then surged by 93.63% to $128.4 million in 2026.
• Business Quant data shows PALI's Equity Average at $128.4 million in Q1 2026, $66.3 million in Q4 2025, and $2.9 million in Q3 2025.